News | October 23, 2022
Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
ZS and Quartic will collaborate to help drive resilience, increase adoption of Industry 4.0 and improve predictive decision-making across manufacturing
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Subscribe To Our Newsletter & Stay Updated
